New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?

Andrea Messori; Valeria  Fadda; Roberta  Gatto; Dario  Maratea; Sabrina  Trippoli

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Home

Instructions

APC

Authors Guide Submit Manuscript

Outlines

Abstract
References
Copyright

New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?

Author(s):

Andrea Messori^1,*,

Valeria Fadda¹,

Roberta Gatto¹,

Dario Maratea¹,

Sabrina Trippoli¹

1HTA Unit, ESTAV Toscana Centro, Regional Health Service, 50100 Firenze, Italy

International Cardiovascular Research Journal:Vol. 8, issue 3; e11104

Published online:Sep 30, 2014

Article type:Brief Report

Received:Feb 21, 2017

Accepted:Mar 01, 2014

How to Cite:Messori A, Fadda V, Gatto R, Maratea D, Trippoli S. New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?. Int Cardiovasc Res J. 2017;8(3):e11104. doi:

Abstract

Background: After an acute coronary syndrome, dual antiplatelet therapy with clopidogrel plus aspirin is still a standard of care, but several new approaches have been investigated.

Objectives: The present study re-examined the studies published thus far on this topic to evaluate the effectiveness of dual antiplatelet therapy in comparison to some of these new approaches (mainly, ticagrelor + aspirin and dual therapy plus a new oral anticoagulant [NOAC]; i.e., “triple therapy”).

Materials and Methods: The clinical material was directly derived from that reported in recent meta-analyses. Our re-analysis relied on standard equivalence methods in which interpretation is based on Relative Risks (RRs) along with their 95% Confidence Intervals (CI). The equivalence margins employed in our statistical testing were directly derived from those reported in randomized studies.

Results: The equivalence margins were initially set at RR ranging from 0.775 to 1.29. According to these margins, triple therapy based on any NOAC proved to be superior to dual therapy alone, but at the same time demonstrated its equivalence with dual therapy. The results for apixaban-based triple therapy were inconclusive (not superior, not not-inferior, not equivalent and, of course, not inferior to the controls). Those for rivaroxaban-based triple therapy showed that this combination treatment was superior to dual therapy alone and failed to meet the criterion of equivalence. In the comparison between rivaroxaban-based triple therapy and ticagrelor + aspirin, the RR was 1 and its 95% CI remained within a post-hoc margin of ± 15%.

Conclusions: Even if one considers the most effective NOAC in combination with clopidogrel + ticagrelor, this triple therapy is not more effective than ticagrelor + aspirin. On the other hand, the increased risk of bleeding with triple regimens is well demonstrated. We therefore conclude that these triple regimens did not play any important roles in the patients experiencing an acute coronary syndrome.

Keywords

Anticoagulants

Acute Coronary Syndrome

Rivaroxaban

Ticagrelor

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

Safety of enoxaparin versus unfractioned heparin in patients undergoing percutaneous coronary intervention using drug eluting stents: A pilot study

Mohammad Javad Zibaeenezhad,

H Kamfiroozi,

Kamran Aghasadeghi

Zibaeenezhad MJ, Kamfiroozi H, Aghasadeghi K. Safety of enoxaparin versus unfractioned heparin in patients undergoing percutaneous coronary intervention using drug eluting stents: A pilot study. Int Cardiovasc Res J. 2018;1(3):e79524. doi:

30

Apr

2016

Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review

Reza Ganji,

Shahram Ala,

Mohsen Aarabi,

Babak Baghery,

Ebrahim Salehifar

Ganji R, Ala S, Aarabi M, Baghery B, Salehifar E. Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review. Iran J Pharm Res. 2016;15(2):e125175. doi: https://doi.org/10.22037/ijpr.2016.1867

20

Oct

2024

Comparative Analysis of Ticagrelor and Clopidogrel Effects on Medication Adherence, Adverse Events, and Laboratory Parameters in Iranian Acute Coronary Syndrome Patients Post-PCI

Vida Hamrahi,

Mehdi Pishgahi,

Alireza Javan,

Roya Hamrahi,

Mohamad Esmail Ghaidari

Hamrahi V, Pishgahi M, Javan A, Hamrahi R, Ghaidari ME. Comparative Analysis of Ticagrelor and Clopidogrel Effects on Medication Adherence, Adverse Events, and Laboratory Parameters in Iranian Acute Coronary Syndrome Patients Post-PCI. Int J Cardiovasc Pract. 2024;9(2):e150332. doi: https://doi.org/10.5812/intjcardiovascpract-150332

30

Jun

2009

Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome

S Abdi,

M Momtahen,

F Javadzadeh,

BF Farsad,

AS Kazzazi,

, Sharifian

,et al.

Abdi S, Momtahen M, Javadzadeh F, Farsad B, Kazzazi A, et al. Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome. Int Cardiovasc Res J. 2009;3(2):e68402. doi:

19

Apr

2022

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial

Ilad Alavi-Darazam,

Kimia Forouhar,

Omid Moradi,

Ali Saffaei,

Sara Asadi,

Zahra Sahraei

Alavi-Darazam I, Forouhar K, Moradi O, Saffaei A, Asadi S, et al. Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial. Iran J Pharm Res. 2022;21(1):e126555. doi: https://doi.org/10.5812/ijpr-126555

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 4 days ago
Scopus by Title: 6
Last Update: 4 days ago
Scopus by Title (Ref): 6
Last Update: 4 days ago
CrossRef: 0
Last Update: 3 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Andrea Messori:[PubMed][Scholar]
Valeria Fadda:[PubMed][Scholar]
Roberta Gatto:[PubMed][Scholar]
Dario Maratea:[PubMed][Scholar]
Sabrina Trippoli:[PubMed][Scholar]

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Outlines

New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?

Abstract

Fulltext

References

Similar Articles

Safety of enoxaparin versus unfractioned heparin in patients undergoing percutaneous coronary intervention using drug eluting stents: A pilot study

Comparison of Dabigatran vs. Warfarin in Acute Vnous Thromboemboly: Systematic Review

Comparative Analysis of Ticagrelor and Clopidogrel Effects on Medication Adherence, Adverse Events, and Laboratory Parameters in Iranian Acute Coronary Syndrome Patients Post-PCI

Platelet GP IIb/IIIa Receptor Inhibition by Eptifibatide in non ST-elevation MI-Acute Coronary Syndrome

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial

Last Update: 4 days ago

Last Update: 4 days ago

Last Update: 4 days ago

Last Update: 3 days ago